Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

The NFκB pathway promotes tamoxifen tolerance and disease recurrence in estrogen receptor positive breast cancers.

Kastrati I, Joosten SEP, Semina SE, Alejo LH, Brovkovych SD, Stender JD, Horlings HM, Kok M, Alarid ET, Greene GL, Linn SC, Zwart W, Frasor J.

Mol Cancer Res. 2020 Apr 3. pii: molcanres.1082.2019. doi: 10.1158/1541-7786.MCR-19-1082. [Epub ahead of print]

PMID:
32245803
2.

Endonuclease FEN1 coregulates ERα activity and provides a novel drug interface in tamoxifen resistant breast cancer.

Flach KD, Periyasamy M, Jadhav A, Dorjsuren D, Siefert JC, Hickey TE, Opdam M, Patel H, Canisius S, Wilson DM, Donaldson Collier M, Prekovic S, Nieuwland M, Kluin RJ, Zakharov AV, Wesseling J, Wessels LFA, Linn SC, Tilley WD, Simeonov A, Ali S, Zwart W.

Cancer Res. 2020 Mar 19. pii: canres.2207.2019. doi: 10.1158/0008-5472.CAN-19-2207. [Epub ahead of print]

PMID:
32193286
3.

Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer.

Zhou S, Hawley JR, Soares F, Grillo G, Teng M, Madani Tonekaboni SA, Hua JT, Kron KJ, Mazrooei P, Ahmed M, Arlidge C, Yun HY, Livingstone J, Huang V, Yamaguchi TN, Espiritu SMG, Zhu Y, Severson TM, Murison A, Cameron S, Zwart W, van der Kwast T, Pugh TJ, Fraser M, Boutros PC, Bristow RG, He HH, Lupien M.

Nat Commun. 2020 Jan 23;11(1):441. doi: 10.1038/s41467-020-14318-9.

4.

TRPS1 acts as a context-dependent regulator of mammary epithelial cell growth/differentiation and breast cancer development.

Cornelissen LM, Drenth AP, van der Burg E, de Bruijn R, Pritchard CEJ, Huijbers IJ, Zwart W, Jonkers J.

Genes Dev. 2020 Feb 1;34(3-4):179-193. doi: 10.1101/gad.331371.119. Epub 2019 Dec 26.

PMID:
31879358
5.

A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population.

Badrising SK, Louhanepessy RD, van der Noort V, Coenen JLLM, Hamberg P, Beeker A, Wagenaar N, Lam MGEH, Celik F, Loosveld OJL, Oostdijk A, Zuetenhorst H, Haanen JB, Vegt E, Zwart W, Bergman AM; ROTOR investigators and the Dutch Uro-Oncology Study group (DUOS15101).

Int J Cancer. 2019 Dec 25. doi: 10.1002/ijc.32851. [Epub ahead of print]

PMID:
31875956
6.

TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth.

Palit SA, Vis D, Stelloo S, Lieftink C, Prekovic S, Bekers E, Hofland I, Šuštić T, Wolters L, Beijersbergen R, Bergman AM, Győrffy B, Wessels LF, Zwart W, van der Heijden MS.

Elife. 2019 Dec 19;8. pii: e47430. doi: 10.7554/eLife.47430.

7.

Androgen modulation of XBP1 is functionally driving part of the AR transcriptional program.

Stelloo S, Linder S, Nevedomskaya E, Valle-Encinas E, de Rink I, Wessels LFA, van der Poel H, Bergman AM, Zwart W.

Endocr Relat Cancer. 2020 Feb;27(2):67-79. doi: 10.1530/ERC-19-0181.

PMID:
31804970
8.

The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.

van Dessel LF, van Riet J, Smits M, Zhu Y, Hamberg P, van der Heijden MS, Bergman AM, van Oort IM, de Wit R, Voest EE, Steeghs N, Yamaguchi TN, Livingstone J, Boutros PC, Martens JWM, Sleijfer S, Cuppen E, Zwart W, van de Werken HJG, Mehra N, Lolkema MP.

Nat Commun. 2019 Nov 20;10(1):5251. doi: 10.1038/s41467-019-13084-7.

9.

Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors.

Mazrooei P, Kron KJ, Zhu Y, Zhou S, Grillo G, Mehdi T, Ahmed M, Severson TM, Guilhamon P, Armstrong NS, Huang V, Yamaguchi TN, Fraser M, van der Kwast T, Boutros PC, He HH, Bergman AM, Bristow RG, Zwart W, Lupien M.

Cancer Cell. 2019 Dec 9;36(6):674-689.e6. doi: 10.1016/j.ccell.2019.10.005. Epub 2019 Nov 14.

PMID:
31735626
10.

Exogenous ERα Expression in the Mammary Epithelium Decreases Over Time and Does Not Contribute to p53-Deficient Mammary Tumor Formation in Mice.

Cornelissen LM, Henneman L, Drenth AP, Schut E, de Bruijn R, Klarenbeek S, Zwart W, Jonkers J.

J Mammary Gland Biol Neoplasia. 2019 Dec;24(4):305-321. doi: 10.1007/s10911-019-09437-z. Epub 2019 Nov 15.

PMID:
31729597
11.

Genomic data integration by WON-PARAFAC identifies interpretable factors for predicting drug-sensitivity in vivo.

Kim Y, Bismeijer T, Zwart W, Wessels LFA, Vis DJ.

Nat Commun. 2019 Nov 6;10(1):5034. doi: 10.1038/s41467-019-13027-2.

12.

IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer.

Kruger DT, Alexi X, Opdam M, Schuurman K, Voorwerk L, Sanders J, van der Noort V, Boven E, Zwart W, Linn SC.

Int J Cancer. 2020 Apr 15;146(8):2348-2359. doi: 10.1002/ijc.32668. Epub 2019 Oct 6.

13.

A CRISPR-Cas9 screen identifies essential CTCF anchor sites for estrogen receptor-driven breast cancer cell proliferation.

Korkmaz G, Manber Z, Lopes R, Prekovic S, Schuurman K, Kim Y, Teunissen H, Flach K, Wit E, Galli GG, Zwart W, Elkon R, Agami R.

Nucleic Acids Res. 2019 Oct 10;47(18):9557-9572. doi: 10.1093/nar/gkz675.

14.

Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis.

Wellenstein MD, Coffelt SB, Duits DEM, van Miltenburg MH, Slagter M, de Rink I, Henneman L, Kas SM, Prekovic S, Hau CS, Vrijland K, Drenth AP, de Korte-Grimmerink R, Schut E, van der Heijden I, Zwart W, Wessels LFA, Schumacher TN, Jonkers J, de Visser KE.

Nature. 2019 Aug;572(7770):538-542. doi: 10.1038/s41586-019-1450-6. Epub 2019 Jul 31.

15.

GATA3 Truncating Mutations Promote Cistromic Re-Programming In Vitro, but Not Mammary Tumor Formation in Mice.

Cornelissen LM, de Bruijn R, Henneman L, Kim Y, Zwart W, Jonkers J.

J Mammary Gland Biol Neoplasia. 2019 Sep;24(3):271-284. doi: 10.1007/s10911-019-09432-4. Epub 2019 Jun 19.

PMID:
31218575
16.

Identification of mineralocorticoid receptor target genes in the mouse hippocampus.

van Weert LTCM, Buurstede JC, Sips HCM, Vettorazzi S, Mol IM, Hartmann J, Prekovic S, Zwart W, Schmidt MV, Roozendaal B, Tuckermann JP, Sarabdjitsingh RA, Meijer OC.

J Neuroendocrinol. 2019 Aug;31(8):e12735. doi: 10.1111/jne.12735. Epub 2019 Jun 14.

17.

CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.

Augello MA, Liu D, Deonarine LD, Robinson BD, Huang D, Stelloo S, Blattner M, Doane AS, Wong EWP, Chen Y, Rubin MA, Beltran H, Elemento O, Bergman AM, Zwart W, Sboner A, Dephoure N, Barbieri CE.

Cancer Cell. 2019 May 13;35(5):817-819. doi: 10.1016/j.ccell.2019.04.012. No abstract available.

PMID:
31085180
18.

CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.

Augello MA, Liu D, Deonarine LD, Robinson BD, Huang D, Stelloo S, Blattner M, Doane AS, Wong EWP, Chen Y, Rubin MA, Beltran H, Elemento O, Bergman AM, Zwart W, Sboner A, Dephoure N, Barbieri CE.

Cancer Cell. 2019 Apr 15;35(4):603-617.e8. doi: 10.1016/j.ccell.2019.03.001. Epub 2019 Mar 28. Erratum in: Cancer Cell. 2019 May 13;35(5):817-819.

PMID:
30930119
19.

Androgen receptor enhancer usage and the chromatin regulatory landscape in human prostate cancers.

Stelloo S, Bergman AM, Zwart W.

Endocr Relat Cancer. 2019 May;26(5):R267-R285. doi: 10.1530/ERC-19-0032. Review.

PMID:
30865928
20.

Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES.

Szijgyarto Z, Flach KD, Opdam M, Palmieri C, Linn SC, Wesseling J, Ali S, Bliss JM, Cheang MCU, Zwart W, Coombes RC.

Breast Cancer Res Treat. 2019 May;175(1):149-163. doi: 10.1007/s10549-018-05110-x. Epub 2019 Jan 24.

21.

Frequent clonal relations between metastases and non-index prostate cancer lesions.

Kneppers J, Krijgsman O, Melis M, de Jong J, Peeper DS, Bekers E, van der Poel HG, Zwart W, Bergman AM.

JCI Insight. 2019 Jan 24;4(2). pii: 124756. doi: 10.1172/jci.insight.124756. [Epub ahead of print]

22.

Optimized ChIP-seq method facilitates transcription factor profiling in human tumors.

Singh AA, Schuurman K, Nevedomskaya E, Stelloo S, Linder S, Droog M, Kim Y, Sanders J, van der Poel H, Bergman AM, Wessels LF, Zwart W.

Life Sci Alliance. 2018 Dec 28;2(1):e201800115. doi: 10.26508/lsa.201800115. eCollection 2019 Feb.

23.

Integrative epigenetic taxonomy of primary prostate cancer.

Stelloo S, Nevedomskaya E, Kim Y, Schuurman K, Valle-Encinas E, Lobo J, Krijgsman O, Peeper DS, Chang SL, Feng FY, Wessels LFA, Henrique R, Jerónimo C, Bergman AM, Zwart W.

Nat Commun. 2018 Nov 21;9(1):4900. doi: 10.1038/s41467-018-07270-2.

24.

ERα activity depends on interaction and target site corecruitment with phosphorylated CREB1.

Berto M, Jean V, Zwart W, Picard D.

Life Sci Alliance. 2018 Jun 7;1(3):e201800055. doi: 10.26508/lsa.201800055. eCollection 2018 Jun.

25.

Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond

Linder S, van der Poel HG, Bergman AM, Zwart W, Prekovic S.

Endocr Relat Cancer. 2018 Oct 31;26(1):R31-R52. doi: 10.1530/ERC-18-0289.

26.

Molecular underpinnings of enzalutamide resistance

Prekovic S, van den Broeck T, Linder S, van Royen ME, Houtsmuller AB, Handle F, Joniau S, Zwart W, Claessens F.

Endocr Relat Cancer. 2018 Nov 1;25(11):R545–R557. doi: 10.1530/ERC-17-0136.

PMID:
30306781
27.

CUEDC1 is a primary target of ERα essential for the growth of breast cancer cells.

Lopes R, Korkmaz G, Revilla SA, van Vliet R, Nagel R, Custers L, Kim Y, van Breugel PC, Zwart W, Moumbeini B, Manber Z, Elkon R, Agami R.

Cancer Lett. 2018 Nov 1;436:87-95. doi: 10.1016/j.canlet.2018.08.018. Epub 2018 Aug 23.

28.

Nuclear Receptor Nur77 Limits the Macrophage Inflammatory Response through Transcriptional Reprogramming of Mitochondrial Metabolism.

Koenis DS, Medzikovic L, van Loenen PB, van Weeghel M, Huveneers S, Vos M, Evers-van Gogh IJ, Van den Bossche J, Speijer D, Kim Y, Wessels L, Zelcer N, Zwart W, Kalkhoven E, de Vries CJ.

Cell Rep. 2018 Aug 21;24(8):2127-2140.e7. doi: 10.1016/j.celrep.2018.07.065.

29.

FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome.

Schrijver W, Schuurman K, van Rossum A, Droog M, Jeronimo C, Salta S, Henrique R, Wesseling J, Moelans C, Linn SC, van den Heuvel M, van Diest P, Zwart W.

Mol Oncol. 2018 Nov;12(11):1884-1894. doi: 10.1002/1878-0261.12353. Epub 2018 Oct 12.

30.

Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug Conjugates.

Schunselaar LM, Monkhorst K, van der Noort V, Wijdeven R, Peters D, Zwart W, Neefjes J, Baas P.

J Thorac Oncol. 2018 Oct;13(10):1577-1587. doi: 10.1016/j.jtho.2018.06.008. Epub 2018 Jun 27.

31.

BRCA1-associated mammary tumorigenesis is dependent on estrogen rather than progesterone signaling.

van de Ven M, Liu X, van der Burg E, Klarenbeek S, Alexi X, Zwart W, Dijcks F, Bouwman P, Jonkers J.

J Pathol. 2018 Sep;246(1):41-53. doi: 10.1002/path.5105. Epub 2018 Jul 4.

PMID:
29877575
32.

Loss of androgen receptor signaling in prostate cancer-associated fibroblasts (CAFs) promotes CCL2- and CXCL8-mediated cancer cell migration.

Cioni B, Nevedomskaya E, Melis MHM, van Burgsteden J, Stelloo S, Hodel E, Spinozzi D, de Jong J, van der Poel H, de Boer JP, Wessels LFA, Zwart W, Bergman AM.

Mol Oncol. 2018 Aug;12(8):1308-1323. doi: 10.1002/1878-0261.12327. Epub 2018 Jul 10.

33.

Androgen receptor moonlighting in the prostate cancer microenvironment.

Cioni B, Zwart W, Bergman AM.

Endocr Relat Cancer. 2018 Jun;25(6):R331-R349. doi: 10.1530/ERC-18-0042. Epub 2018 Apr 4.

PMID:
29618577
34.

Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer.

Severson TM, Kim Y, Joosten SEP, Schuurman K, van der Groep P, Moelans CB, Ter Hoeve ND, Manson QF, Martens JW, van Deurzen CHM, Barbe E, Hedenfalk I, Bult P, Smit VTHBM, Linn SC, van Diest PJ, Wessels L, Zwart W.

Nat Commun. 2018 Feb 2;9(1):482. doi: 10.1038/s41467-018-02856-2.

35.

Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance.

Martin LA, Ribas R, Simigdala N, Schuster E, Pancholi S, Tenev T, Gellert P, Buluwela L, Harrod A, Thornhill A, Nikitorowicz-Buniak J, Bhamra A, Turgeon MO, Poulogiannis G, Gao Q, Martins V, Hills M, Garcia-Murillas I, Fribbens C, Patani N, Li Z, Sikora MJ, Turner N, Zwart W, Oesterreich S, Carroll J, Ali S, Dowsett M.

Nat Commun. 2017 Nov 30;8(1):1865. doi: 10.1038/s41467-017-01864-y.

36.

Chemical Profiling of Primary Mesothelioma Cultures Defines Subtypes with Different Expression Profiles and Clinical Responses.

Schunselaar LM, Quispel-Janssen JMMF, Kim Y, Alifrangis C, Zwart W, Baas P, Neefjes J.

Clin Cancer Res. 2018 Apr 1;24(7):1761-1770. doi: 10.1158/1078-0432.CCR-17-1345. Epub 2017 Oct 24.

37.

Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis.

Stelloo S, Nevedomskaya E, Kim Y, Hoekman L, Bleijerveld OB, Mirza T, Wessels LFA, van Weerden WM, Altelaar AFM, Bergman AM, Zwart W.

Oncogene. 2018 Jan 18;37(3):313-322. doi: 10.1038/onc.2017.330. Epub 2017 Sep 18.

PMID:
28925401
38.

Loss of steroid hormone receptors is common in malignant pleural and peritoneal effusions of breast cancer patients treated with endocrine therapy.

Schrijver WAME, Schuurman K, van Rossum A; Dutch Distant Breast Cancer Metastases Consortium, Peeters T, Ter Hoeve N, Zwart W, van Diest PJ, Moelans CB.

Oncotarget. 2017 Feb 20;8(33):55550-55561. doi: 10.18632/oncotarget.15548. eCollection 2017 Aug 15.

39.

Targeting BAP1: a new paradigm for mesothelioma.

Schunselaar LM, Zwart W, Baas P.

Lung Cancer. 2017 Jul;109:145-146. doi: 10.1016/j.lungcan.2017.03.005. Epub 2017 Mar 18.

PMID:
28342657
40.

Estrogen receptor α wields treatment-specific enhancers between morphologically similar endometrial tumors.

Droog M, Nevedomskaya E, Dackus GM, Fles R, Kim Y, Hollema H, Mourits MJ, Nederlof PM, van Boven HH, Linn SC, van Leeuwen FE, Wessels LF, Zwart W.

Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):E1316-E1325. doi: 10.1073/pnas.1615233114. Epub 2017 Feb 6. Erratum in: Proc Natl Acad Sci U S A. 2018 Jan 22;:. Mourits, Marian [corrected to Mourits, Marian J].

41.

A review of estrogen receptor/androgen receptor genomics in male breast cancer.

Severson TM, Zwart W.

Endocr Relat Cancer. 2017 Mar;24(3):R27-R34. doi: 10.1530/ERC-16-0225. Epub 2017 Jan 6. Review.

PMID:
28062545
42.

An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome.

de Vries Schultink AH, Alexi X, van Werkhoven E, Madlensky L, Natarajan L, Flatt SW, Zwart W, Linn SC, Parker BA, Wu AH, Pierce JP, Huitema AD, Beijnen JH.

Breast Cancer Res Treat. 2017 Feb;161(3):567-574. doi: 10.1007/s10549-016-4083-6. Epub 2016 Dec 22.

43.

The Estrogen Receptor α-Cistrome Beyond Breast Cancer.

Droog M, Mensink M, Zwart W.

Mol Endocrinol. 2016 Oct;30(10):1046-1058. Epub 2016 Aug 4. Review.

44.

The Effects of Enzalutamide Monotherapy on Multiparametric 3T MR Imaging in Prostate Cancer.

Van der Roest RC, van Houdt PJ, Heijmink SW, de Jong J, Bergman AM, Zwart W, van der Heide UA, van der Poel HG.

Urol Case Rep. 2016 May 26;7:67-9. doi: 10.1016/j.eucr.2016.04.010. eCollection 2016 Jul.

45.

Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas.

Droog M, Nevedomskaya E, Kim Y, Severson T, Flach KD, Opdam M, Schuurman K, Gradowska P, Hauptmann M, Dackus G, Hollema H, Mourits M, Nederlof P, van Boven H, Linn SC, Wessels L, van Leeuwen FE, Zwart W.

Cancer Res. 2016 Jul 1;76(13):3773-84. doi: 10.1158/0008-5472.CAN-14-1813. Epub 2016 May 6. Erratum in: Cancer Res. 2018 May 1;78(9):2446.

46.

Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation.

Severson TM, Nevedomskaya E, Peeters J, Kuilman T, Krijgsman O, van Rossum A, Droog M, Kim Y, Koornstra R, Beumer I, Glas AM, Peeper D, Wesseling J, Simon IM, Wessels L, Linn SC, Zwart W.

Oncotarget. 2016 Jun 7;7(23):33901-18. doi: 10.18632/oncotarget.8983.

47.

mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma.

Stelloo S, Sanders J, Nevedomskaya E, de Jong J, Peters D, van Leenders GJ, Jenster G, Bergman AM, Zwart W.

Oncotarget. 2016 May 31;7(22):32916-24. doi: 10.18632/oncotarget.8767.

48.

Androgen receptor DNA binding and chromatin accessibility profiling in prostate cancer.

Nevedomskaya E, Stelloo S, van der Poel HG, de Jong J, Wessels LF, Bergman AM, Zwart W.

Genom Data. 2015 Dec 28;7:124-6. doi: 10.1016/j.gdata.2015.12.020. eCollection 2016 Mar.

49.

The first decade of estrogen receptor cistromics in breast cancer.

Flach KD, Zwart W.

J Endocrinol. 2016 May;229(2):R43-56. doi: 10.1530/JOE-16-0003. Epub 2016 Feb 23. Review.

PMID:
26906743
50.

Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma.

Heynen GJ, Nevedomskaya E, Palit S, Jagalur Basheer N, Lieftink C, Schlicker A, Zwart W, Bernards R, Bajpe PK.

Mol Cancer Res. 2016 May;14(5):411-22. doi: 10.1158/1541-7786.MCR-15-0291-T. Epub 2016 Jan 19.

Supplemental Content

Support Center